Get started
Author

Sachin Vadgama

Observed names: S Vadgama, S. Vadgama, Vadgama, Sachin
ORCID: 0000-0002-9138-8471
Observed ORCID: 0000-0002-9138-8471
OpenAlex ID: A5067259603
The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial
2022 · Miguel-Angel Perales, John Kuruvilla, et al. · Transplantation and Cellular Therapy · 37
Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis
2025 · Andrea P. Chung, Jason T. Shafrin, et al. · Blood Advances · 29
PDF
An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States
2023 · Olalekan O. Oluwole, Anik R. Patel, et al. · Journal of Medical Economics · 21
PDF
Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1
2022 · Sachin Vadgama, Jess Mann, et al. · Value in Health · 18
PDF
Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial
2023 · Anne Sofie Ledgaard Loftager, Anne Danø, et al. · Journal of Medical Economics · 16
PDF
“Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes
2024 · Sachin Vadgama, Marcelo C. Pasquini, et al. · Blood Advances · 14
Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole–body magnetic resonance imaging in radio-recurrent prostate cancer
2019 · Sola Adeleke, Arash Latifoltojar, et al. · BMC Medical Imaging · 14
PDF
PPM3 Cost-Effectiveness of Axicabtagene Ciloleucel (AXI-CEL) VS Standard of Care for Adult Patients with Relapsed or Refractory Diffuse Large B-CELL Lymphoma in Sweden, Norway, Finland, and Denmark
2020 · K. Karampampa, E. Stene, et al. · Value in Health · 4
PDF
Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
2024 · Veit L. Buecklein, Francis A. Ayuk, et al. · Blood · 2
Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)
2024 · Armin Ghobadi, Theodora Anagnostou, et al. · Transplantation and Cellular Therapy · 2
Cost-Effectiveness of Axicabtagene Ciloleucel As Second-Line Therapy for Patients Large B-Cell Lymphoma (LBCL) in the United States
2022 · Miguel-Angel Perales, John Kuruvilla, et al. · Transplantation and Cellular Therapy · 2
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe
2026 · Yan Zhi Tan, Emily Breislin, et al. · Journal of Medical Economics · 1
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL
2025 · Sam Harper, Daniela Afonso, et al. · PharmacoEconomics · 1
PDF
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
2024 · Raúl Córdoba, Lucía López-Corral, et al. · Cancers · 1
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe
2026 · Tan, Yan Zhi, Breislin, Emily, et al. · Figshare
EE414 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in the Netherlands
2024 · H Burghoorn, Y. Rodriguez-Guadarrama, et al. · Value in Health
PDF
EE27 A Best Practice Guide to Cost-Effectiveness Modelling of CAR Ts in Large B-Cell Lymphoma
2024 · B Doble, S Vadgama, et al. · Value in Health
EE403 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany
2024 · F Kron, L Reimeir, et al. · Value in Health
PDF
EE355 The Impact of Dynamic Mortality on the Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in France
2024 · A Zang, L Chambry, et al. · Value in Health
PDF
EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States
2023 · O. Oluwole, A. Patel, et al. · Value in Health
PDF
‘Don’t keep me waiting’: estimating the impact on lifetime survival and QALYs of reduced vein‐to‐vein time for LBCL patients treated with CAR T in the 3L+ setting
2023 · R. Maziarz, S. Vadgama, et al. · Hematological Oncology
PDF
Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial
2023 · Loftager, Anne Sofie Ledgaard, Danø, Anne, et al. · Figshare
RWD72 Real-World Treatment Pathways of Patients With Diffuse Large B-Cell Lymphoma Receiving Second Line Treatment or Later in the UK, Canada, France, Germany, Italy, and Spain: A Prospective Survey of Physicians
2022 · A Bailey, N Milloy, et al. · Value in Health
Pb2098: ‘real-world’ Treatment Patterns and Pathways of Second Line Diffuse Large B-cell Lymphoma Patients in Uk, Canada, France, Germany, Italy and Spain Using a Prospective Survey of Physicians
2022 · A. Bailey, N. Milloy, et al. · HemaSphere
Cost-Effectiveness Analysis Of Regorafenib In Gastrointestinal Stromal Tumours In England Using Crossover Adjustment Methods
2016 · A Pitcher, E Grabbi, et al. · Value in Health
Works count: 26
Citation count: 161
H-index: 7
I10-index: 7
Year
Topic
Type